Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2076
HCI Group
HCI
$2.32B
| $3.25M | ﹤0.01% |
80,219
-33,900
| -30% | -$1.41M |
|
2077
Silvercrest Asset Management
SAMG
$76.1M
| $3.23M | ﹤0.01% |
230,424
+13,068
| +6% | +$182K |
|
2078
Elanco Animal Health
ELAN
$13.2B
| $3.22M | ﹤0.01% |
+95,200
| New | +$3.09M |
|
2079
Sunoco
SUN
$14.3B
| $3.21M | ﹤0.01% |
102,700
-37,700
| -27% | -$1.16M |
|
2080
Collegium Pharmaceutical
COLL
$1.17B
| $3.21M | ﹤0.01% |
+244,100
| New | +$3.26M |
|
2081
Puma Biotechnology
PBYI
$402M
| $3.21M | ﹤0.01% |
252,200
+160,300
| +174% | +$3.69M |
|
2082
FB Financial Corp
FBK
$3B
| $3.2M | ﹤0.01% |
87,500
+11,900
| +16% | +$420K |
|
|
DALN
2083
DELISTED
DallasNews
DALN
| $3.2M | ﹤0.01% |
216,918
+5,665
| +3% | +$86.8K |
|
2084
Stantec
STN
$7.92B
| $3.2M | ﹤0.01% |
133,500
+18,600
| +16% | +$449K |
|
2085
Distribution Solutions Group
DSGR
$1.6B
| $3.2M | ﹤0.01% |
174,200
+66,422
| +62% | +$1.14M |
|
|
VIA
2086
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
| $3.19M | ﹤0.01% |
57,062
+40,162
| +238% | +$2.01M |
|
2087
AmeriServ Financial
ASRV
$77.5M
| $3.18M | ﹤0.01% |
766,391
-1,976
| -0.3% | -$8.16K |
|
|
QUMU
2088
DELISTED
Qumu Corp.
QUMU
| $3.18M | ﹤0.01% |
765,371
+84,190
| +12% | +$284K |
|
|
BNFT
2089
DELISTED
Benefitfocus, Inc.
BNFT
| $3.17M | ﹤0.01% |
116,945
-18,894
| -14% | -$634K |
|
2090
Parker-Hannifin
PH
$121B
| $3.17M | ﹤0.01% |
+18,650
| New | +$3.22M |
|
|
SAFE
2091
Safehold
SAFE
$1.13B
| $3.17M | ﹤0.01% |
+52,408
| New | +$2.51M |
|
|
FOLD
2092
DELISTED
Amicus Therapeutics
FOLD
| $3.17M | ﹤0.01% |
+253,800
| New | +$3.22M |
|
|
EIGR
2093
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.17M | ﹤0.01% |
9,954
+656
| +7% | +$227K |
|
|
CBLK
2094
DELISTED
Carbon Black, Inc. Common Stock
CBLK
| $3.16M | ﹤0.01% |
+189,200
| New | +$2.9M |
|
|
NBRV
2095
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $3.16M | ﹤0.01% |
5,197
+1,774
| +52% | +$1.09M |
|
|
CWBC
2096
Community West Bancshares
CWBC
$682M
| $3.13M | ﹤0.01% |
145,592
+26,211
| +22% | +$522K |
|
|
CBM
2097
DELISTED
Cambrex Corporation
CBM
| $3.12M | ﹤0.01% |
66,700
-57,700
| -46% | -$2.42M |
|
2098
Southwest Gas
SWX
$6.54B
| $3.12M | ﹤0.01% |
34,800
+30,584
| +725% | +$2.6M |
|
2099
AMES National
ATLO
$269M
| $3.12M | ﹤0.01% |
115,021
+6,421
| +6% | +$173K |
|
2100
Corvus Pharmaceuticals
CRVS
$1.11B
| $3.12M | ﹤0.01% |
833,098
+51,398
| +7% | +$201K |
|
Similar funds
Renaissance Technologies's Q2 2019 Portfolio in Review
As of Q2 2019, Renaissance Technologies held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Renaissance Technologies's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Renaissance Technologies's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Renaissance Technologies added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Renaissance Technologies's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Renaissance Technologies fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Renaissance Technologies's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Renaissance Technologies opened 495 new positions and closed 397 in Q2 2019.
- Renaissance Technologies's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.